IONS Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Ionis Pharmaceuticals Inc had $944M of revenue in fiscal 2025, up 33.8% on the year before. Over five years, revenue changed +5.3% a year on average.
Last close Β· Oct 23, 2026
$42.93
2.2%Hi! I read Ionis Pharmaceuticals Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+33.8%
Yes. Sales grew 33.8% last year.
Does it make a profit?
β40.4%
No. It lost money last year.
Does profit turn into cash?
β33.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Ionis Pharmaceuticals Inc had $944M of revenue in fiscal 2025, up 33.8% on the year before. Over five years, revenue changed +5.3% a year on average. Its operating margin was β40.4%, up 26.9Β pts: of every 100 in sales, about β40 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Ionis Pharmaceuticals Inc lost $381M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$320M in fiscal 2025, β33.9% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $1.1M and sold $133M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$1.1M
1 insider
Sold, 12 months
$133M
19 insiders
Of sales under plans
83%
$111M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 16, 2026 | Eric SwayzeEVP Research | Sold | 53 | $43.54 | $0.0M | Form 4 |
| Oct 16, 2026 | Shannon L. DeversEVP, Chief Human Resources Ofc | Sold | 1,357 | $43.54 | $0.1M | Form 4 |
| Jul 31, 2026 | Michael R HaydenDirector | Bought | 5,000 | $51.60 | $0.3M | Form 4 |
| Jul 30, 2026 | Michael R HaydenDirector | Bought | 15,000 | $53.38 | $0.8M | Form 4 |
| Jul 7, 2026 | Allene M. DiazDirector | Sold plan | 10,111 | $85.42 | $0.9M | Form 4 |
| Jul 7, 2026 | C Frank BennettEVP, Chief Scientific Officer | Sold plan | 20,536 | $84.95 | $1.7M | Form 4 |
| Jul 7, 2026 | Holly B. KordasiewiczEVP, Chief Development Officer | Sold plan | 362 | $84.30 | $0.0M | Form 4 |
| Jul 1, 2026 | Joseph Klein IIIDirector | Sold plan | 11,518 | $79.04 | $0.9M | Form 4 |
| Jun 26, 2026 | Brett P MoniaChief Executive Officer, Director | Sold plan | 50,000 | $80.59 | $4.0M | Form 4 |
| Jun 26, 2026 | Eugene SchneiderEVP, Chf Clinical Develop Ofcr | Sold plan | 26,000 | $81.05 | $2.1M | Form 4 |
| Jun 26, 2026 | Joseph BaroldiEVP, Chief Business Officer | Sold plan | 5,635 | $80.16 | $0.5M | Form 4 |
| Jun 26, 2026 | Patrick R. O'NeilEVP CLO & General Counsel | Sold plan | 3,069 | $80.00 | $0.2M | Form 4 |
| Jun 25, 2026 | Brett P MoniaChief Executive Officer, Director | Sold plan | 21,072 | $78.49 | $1.7M | Form 4 |
| Jun 25, 2026 | Eric SwayzeEVP Research | Sold plan | 10,602 | $79.18 | $0.8M | Form 4 |
| Jun 24, 2026 | Brett P MoniaChief Executive Officer, Director | Sold plan | 14,565 | $78.41 | $1.1M | Form 4 |
| Jun 15, 2026 | Spencer R BerthelsenDirector | Sold plan | 8,000 | $73.49 | $0.6M | Form 4 |
| Jun 12, 2026 | Holly B. KordasiewiczEVP, Chief Development Officer | Sold plan | 60,846 | $73.40 | $4.5M | Form 4 |
| Jun 1, 2026 | Spencer R BerthelsenDirector | Sold plan | 8,000 | $75.67 | $0.6M | Form 4 |
| May 14, 2026 | Brett P MoniaChief Executive Officer, Director | Sold plan | 3,220 | $78.68 | $0.3M | Form 4 |
| May 13, 2026 | Brett P MoniaChief Executive Officer, Director | Sold plan | 1,316 | $78.01 | $0.1M | Form 4 |
| May 4, 2026 | Joseph LoscalzoDirector | Sold plan | 77,289 | $75.06 | $5.8M | Form 4 |
| May 1, 2026 | Joseph Klein IIIDirector | Sold plan | 10,111 | $73.51 | $0.7M | Form 4 |
| Apr 28, 2026 | Joseph BaroldiEVP, Chief Business Officer | Sold plan | 1,626 | $71.79 | $0.1M | Form 4 |
| Apr 16, 2026 | Brian BirchlerEVP, Corp and Development Ops | Sold | 973 | $75.04 | $0.1M | Form 4 |
| Apr 16, 2026 | Joseph BaroldiEVP, Chief Business Officer | Sold | 5,619 | $74.56 | $0.4M | Form 4 |
| Apr 16, 2026 | Kyle JenneEVP, Chf GL Pdt Str Ofcr | Sold | 4,902 | $75.17 | $0.4M | Form 4 |
| Apr 15, 2026 | B Lynne ParshallDirector | Sold plan | 5,000 | $76.27 | $0.4M | Form 4 |
| Apr 2, 2026 | Shannon L. DeversEVP, Chief Human Resources Ofc | Sold plan | 6,193 | $74.05 | $0.5M | Form 4 |
| Apr 1, 2026 | Joseph Klein IIIDirector | Sold plan | 22,321 | $75.54 | $1.7M | Form 4 |
| Mar 19, 2026 | Eugene SchneiderEVP, Chf Clinical Develop Ofcr | Sold plan | 5,812 | $70.97 | $0.4M | Form 4 |
| Mar 17, 2026 | Elizabeth L HougenEVP, Finance & CFO | Sold plan | 10,172 | $73.21 | $0.7M | Form 4 |
| Mar 16, 2026 | Elizabeth L HougenEVP, Finance & CFO | Sold plan | 215,048 | $72.40 | $15.6M | Form 4 |
| Mar 10, 2026 | Brett P MoniaChief Executive Officer, Director | Sold plan | 34,103 | $75.92 | $2.6M | Form 4 |
| Mar 10, 2026 | Kyle JenneEVP, Chf GL Pdt Str Ofcr | Sold plan | 37,277 | $75.85 | $2.8M | Form 4 |
| Mar 9, 2026 | Brett P MoniaChief Executive Officer, Director | Sold plan | 126,670 | $75.20 | $9.5M | Form 4 |
| Mar 9, 2026 | Patrick R. O'NeilEVP CLO & General Counsel | Sold plan | 10,148 | $75.25 | $0.8M | Form 4 |
| Mar 4, 2026 | Joseph BaroldiEVP, Chief Business Officer | Sold plan | 439 | $80.00 | $0.0M | Form 4 |
| Mar 4, 2026 | Joseph LoscalzoDirector | Sold plan | 200 | $80.00 | $0.0M | Form 4 |
| Mar 3, 2026 | Allene M. DiazDirector | Sold plan | 54,878 | $79.35 | $4.4M | Form 4 |
| Mar 3, 2026 | C Frank BennettEVP, Chief Scientific Officer | Sold plan | 85,089 | $79.23 | $6.7M | Form 4 |
| Mar 3, 2026 | Joseph BaroldiEVP, Chief Business Officer | Sold plan | 6,220 | $79.72 | $0.5M | Form 4 |
| Mar 3, 2026 | Joseph Klein IIIDirector | Sold plan | 21,332 | $79.51 | $1.7M | Form 4 |
| Mar 3, 2026 | Joseph LoscalzoDirector | Sold plan | 832 | $80.33 | $0.1M | Form 4 |
| Mar 3, 2026 | Shannon L. DeversEVP, Chief Human Resources Ofc | Sold plan | 20,106 | $79.40 | $1.6M | Form 4 |
| Feb 13, 2026 | Eric SwayzeEVP Research | Sold plan | 15,642 | $81.76 | $1.3M | Form 4 |
| Feb 11, 2026 | B Lynne ParshallDirector | Sold plan | 5,000 | $82.72 | $0.4M | Form 4 |
| Feb 6, 2026 | Brett P MoniaChief Executive Officer, Director | Sold plan | 29,430 | $85.79 | $2.5M | Form 4 |
| Feb 2, 2026 | C Frank BennettEVP, Chief Scientific Officer | Sold plan | 85,089 | $82.93 | $7.1M | Form 4 |
| Jan 30, 2026 | Brett P MoniaChief Executive Officer, Director | Sold | 62,970 | $82.72 | $5.2M | Form 4 |
| Jan 30, 2026 | Brian BirchlerEVP, Corp and Development Ops | Sold | 6,179 | $83.03 | $0.5M | Form 4 |
| Jan 30, 2026 | C Frank BennettEVP, Chief Scientific Officer | Sold | 5,885 | $82.95 | $0.5M | Form 4 |
| Jan 30, 2026 | Elizabeth L HougenEVP, Finance & CFO | Sold | 6,988 | $83.24 | $0.6M | Form 4 |
| Jan 30, 2026 | Eric SwayzeEVP Research | Sold | 6,179 | $82.93 | $0.5M | Form 4 |
| Jan 30, 2026 | Eugene SchneiderEVP, Chf Clinical Develop Ofcr | Sold | 6,179 | $83.45 | $0.5M | Form 4 |
| Jan 30, 2026 | Joseph BaroldiEVP, Chief Business Officer | Sold | 5,296 | $82.96 | $0.4M | Form 4 |
| Jan 30, 2026 | Patrick R. O'NeilEVP CLO & General Counsel | Sold | 6,179 | $83.53 | $0.5M | Form 4 |
| Jan 22, 2026 | Shannon L. DeversEVP, Chief Human Resources Ofc | Sold plan | 3,977 | $81.34 | $0.3M | Form 4 |
| Jan 16, 2026 | Brett P MoniaChief Executive Officer, Director | Sold | 44,034 | $74.82 | $3.3M | Form 4 |
| Jan 16, 2026 | Brian BirchlerEVP, Corp and Development Ops | Sold | 8,480 | $75.11 | $0.6M | Form 4 |
| Jan 16, 2026 | C Frank BennettEVP, Chief Scientific Officer | Sold | 8,977 | $75.15 | $0.7M | Form 4 |
| Jan 16, 2026 | Elizabeth L HougenEVP, Finance & CFO | Sold | 12,922 | $75.22 | $1.0M | Form 4 |
| Jan 16, 2026 | Eric SwayzeEVP Research | Sold | 9,933 | $75.34 | $0.7M | Form 4 |
| Jan 16, 2026 | Eugene SchneiderEVP, Chf Clinical Develop Ofcr | Sold | 9,302 | $75.59 | $0.7M | Form 4 |
| Jan 16, 2026 | Holly B. KordasiewiczEVP, Chief Development Officer | Sold | 4,141 | $75.66 | $0.3M | Form 4 |
| Jan 16, 2026 | Joseph BaroldiEVP, Chief Business Officer | Sold | 8,056 | $75.75 | $0.6M | Form 4 |
| Jan 16, 2026 | Kyle JenneEVP, Chf GL Pdt Str Ofcr | Sold | 1,823 | $75.96 | $0.1M | Form 4 |
| Jan 16, 2026 | Patrick R. O'NeilEVP CLO & General Counsel | Sold | 9,191 | $75.84 | $0.7M | Form 4 |
| Jan 16, 2026 | Shannon L. DeversEVP, Chief Human Resources Ofc | Sold | 8,353 | $75.95 | $0.6M | Form 4 |
| Jan 7, 2026 | Shannon L. DeversEVP, Chief Human Resources Ofc | Sold plan | 44,199 | $85.08 | $3.8M | Form 4 |
| Jan 2, 2026 | Eric SwayzeEVP Research | Sold plan | 23,463 | $79.12 | $1.9M | Form 4 |
| Dec 1, 2025 | Joseph H WenderDirector | Sold plan | 28,000 | $80.82 | $2.3M | Form 4 |
| Nov 25, 2025 | Joseph Klein IIIDirector | Sold plan | 4,000 | $80.00 | $0.3M | Form 4 |
| Nov 25, 2025 | Shannon L. DeversEVP, Chief Human Resources Ofc | Sold plan | 16,777 | $80.91 | $1.4M | Form 4 |
| Nov 19, 2025 | Joan E HermanDirector | Sold | 44,000 | $72.13 | $3.2M | Form 4 |
| Nov 6, 2025 | Brian BirchlerEVP, Corp and Development Ops | Sold plan | 8,000 | $76.17 | $0.6M | Form 4 |
| Nov 6, 2025 | Richard S GearyEVP, Chief Development Officer | Sold plan | 33,038 | $75.72 | $2.5M | Form 4 |
| Nov 5, 2025 | Richard S GearyEVP, Chief Development Officer | Sold plan | 1,601 | $75.01 | $0.1M | Form 4 |
| Nov 3, 2025 | Richard S GearyEVP, Chief Development Officer | Sold plan | 1,680 | $75.05 | $0.1M | Form 4 |
| Oct 31, 2025 | Joseph H WenderDirector | Sold plan | 11,200 | $75.16 | $0.8M | Form 4 |
| Oct 31, 2025 | Joseph LoscalzoDirector | Sold plan | 16,000 | $75.10 | $1.2M | Form 4 |
| Oct 31, 2025 | Richard S GearyEVP, Chief Development Officer | Sold plan | 89,249 | $75.11 | $6.7M | Form 4 |
| Oct 30, 2025 | Joseph H WenderDirector | Sold plan | 16,800 | $73.26 | $1.2M | Form 4 |
| Oct 16, 2025 | Eric SwayzeEVP Research | Sold | 53 | $73.62 | $0.0M | Form 4 |
| Oct 16, 2025 | Shannon L. DeversEVP, Chief Human Resources Ofc | Sold plan | 1,263 | $73.62 | $0.1M | Form 4 |
| Oct 15, 2025 | B Lynne ParshallDirector | Sold plan | 5,000 | $71.74 | $0.4M | Form 4 |
| Oct 15, 2025 | Brian BirchlerEVP, Corp and Development Ops | Sold plan | 12,425 | $72.23 | $0.9M | Form 4 |
| Oct 15, 2025 | Shannon L. DeversEVP, Chief Human Resources Ofc | Sold plan | 6,000 | $72.94 | $0.4M | Form 4 |
| Oct 14, 2025 | Brian BirchlerEVP, Corp and Development Ops | Sold plan | 11,475 | $72.03 | $0.8M | Form 4 |
| Oct 6, 2025 | Brett P MoniaChief Executive Officer, Director | Sold plan | 437 | $69.26 | $0.0M | Form 4 |
| Oct 6, 2025 | Eric SwayzeEVP Research | Sold plan | 6,849 | $69.02 | $0.5M | Form 4 |
| Oct 6, 2025 | Joseph BaroldiEVP, Chief Business Officer | Sold plan | 1,625 | $69.37 | $0.1M | Form 4 |
| Oct 6, 2025 | Patrick R. O'NeilEVP CLO & General Counsel | Sold plan | 13,441 | $69.74 | $0.9M | Form 4 |
| Oct 2, 2025 | Eric SwayzeEVP Research | Sold plan | 12,972 | $66.23 | $0.9M | Form 4 |
| Oct 2, 2025 | Joseph BaroldiEVP, Chief Business Officer | Sold plan | 15,000 | $68.01 | $1.0M | Form 4 |
| Oct 2, 2025 | Patrick R. O'NeilEVP CLO & General Counsel | Sold plan | 64,664 | $67.69 | $4.4M | Form 4 |
| Oct 1, 2025 | Eric SwayzeEVP Research | Sold plan | 14,142 | $66.09 | $0.9M | Form 4 |
| Oct 1, 2025 | Joseph H WenderDirector | Sold plan | 16,800 | $65.50 | $1.1M | Form 4 |
| Sep 30, 2025 | Elizabeth L HougenEVP, Finance & CFO | Sold plan | 49,800 | $65.26 | $3.2M | Form 4 |
| Sep 30, 2025 | Patrick R. O'NeilEVP CLO & General Counsel | Sold plan | 14,827 | $64.68 | $1.0M | Form 4 |
| Sep 30, 2025 | Richard S GearyEVP, Chief Development Officer | Sold plan | 57,900 | $65.24 | $3.8M | Form 4 |
| Sep 29, 2025 | Patrick R. O'NeilEVP CLO & General Counsel | Sold plan | 10,473 | $64.54 | $0.7M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Ionis Pharmaceuticals Inc has $865M more cash than debt.
Cash, debt and the ratios that show how comfortably Ionis Pharmaceuticals Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.1B | $2.0B | $2.3B | $2.3B | $2.7B |
| Debt incl. finance leases | β | $1.2B | $1.3B | $1.3B | $1.8B |
| Debt / equity | β | 2.1x | 3.4x | 2.1x | 3.7x |
| Interest coverage | β3.2x | β50.5x | β27.9x | β28.0x | β22.1x |
| Current ratio | 9.7x | 7.1x | 5.9x | 8.5x | 3.8x |
| Quick ratio | 9.6x | 7.0x | 5.9x | 8.4x | 3.8x |
| Total assets | $2.6B | $2.5B | $3.0B | $3.0B | $3.5B |
| Total liabilities | $1.8B | $2.0B | $2.6B | $2.4B | $3.0B |
| Shareholders' equity | $772M | $573M | $387M | $588M | $489M |
| Net debt (β = net cash) | β | β$793M | β$1.0B | β$1.0B | β$865M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Ionis Pharmaceuticals Inc passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 6 / 9 | 5 / 9 | 5 / 9 | 3 / 9 | 6 / 8 | 0 / 8 | 4 / 9 | 2 / 9 | 3 / 9 |
| Accruals ratio | 5.7% | β15.6% | β16.5% | β2.3% | β17.1% | β2.4% | 0.2% | β2.1% | 1.6% | β3.5% |
| Altman Z'' | 0.53 | 2.00 | 4.15 | 6.01 | 2.65 | 4.20 | 2.28 | 2.22 | 1.80 | 1.12 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $347M | $508M | $600M | $1.1B | $729M | $810M | $587M | $788M | $705M | $944M |
| Gross profit | $347M | $508M | $598M | $1.1B | $717M | $800M | $573M | $779M | $694M | $928M |
| Research and development | $340M | $373M | $412M | $462M | $531M | $638M | β | $900M | $902M | $916M |
| Operating income | β$20.2M | $31.0M | β$61.4M | $366M | β$172M | β$30.2M | β$410M | β$354M | β$475M | β$382M |
| Interest expense | $38.8M | $44.8M | $44.8M | $12.4M | $9.5M | $9.3M | $8.1M | $12.7M | $17.0M | $17.3M |
| Pretax income | β$83.6M | β$16.8M | β$76.2M | $339M | β$135M | β$29.1M | β$258M | β$334M | β$460M | β$380M |
| Income tax | $2.9M | β$6.0M | β$291M | $51.5M | $345M | β$0.6M | $11.7M | $32.3M | β$6.2M | $1.8M |
| Net income | β$60.4M | $0.3M | $274M | $278M | β$444M | β$28.6M | β$270M | β$366M | β$454M | β$381M |
| Net income to common | β | $18.8M | $277M | $281M | β$444M | β | β | β | β | β |
| Diluted EPS | β$0.50 | $0.15 | $2.07 | $1.90 | β$3.18 | β$0.20 | β$1.90 | β$2.56 | β$3.04 | β$2.38 |
| Diluted shares | 0.12B | 0.13B | 0.13B | 0.15B | 0.14B | 0.14B | 0.14B | 0.14B | 0.15B | 0.16B |
| Cash flow | ||||||||||
| Cash from operations | β$112M | $174M | $603M | $346M | $35.9M | $30.8M | β$274M | β$308M | β$501M | β$269M |
| Capital expenditure | $7.1M | $34.8M | $13.6M | $30.9M | $35.1M | $12.0M | $15.7M | $23.8M | $45.3M | $51.4M |
| Free cash flow | β$119M | $139M | $589M | $315M | $0.8M | $18.8M | β$290M | β$331M | β$546M | β$320M |
| Depreciation and amortization | $7.5M | $6.7M | $10.7M | $12.5M | $13.4M | $15.5M | $14.3M | $10.3M | $9.6M | $10.0M |
| Stock-based compensation | $72.1M | $86.0M | $131M | $147M | $230M | $121M | $100M | $106M | $130M | $134M |
| Share buybacks | β | $0.0M | $0.0M | $34.4M | $90.5M | $0.0M | $0.0M | β | β | β |
| Dividends and buybacks | β | $0.0M | $0.0M | $34.4M | $90.5M | $0.0M | $0.0M | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $665M | $1.0B | $2.1B | $2.5B | $1.9B | $2.1B | $2.0B | $2.3B | $2.3B | $2.7B |
| Total debt | $1.2M | $1.6M | $13.7M | $788M | $840M | β | $1.2B | $1.3B | $1.3B | $1.8B |
| Current assets | $798M | $1.2B | $2.2B | $2.7B | $2.1B | $2.3B | $2.2B | $2.6B | $2.6B | $3.0B |
| Current liabilities | $134M | $244M | $280M | $273M | $599M | $241M | $312M | $448M | $309M | $782M |
| Inventory | β | $10.0M | $8.6M | $18.2M | $22.0M | $24.8M | $22.0M | $7.4M | $12.5M | $10.0M |
| Property and equipment, net | $92.8M | $122M | $132M | $154M | $181M | $178M | $74.3M | $71.0M | $94.3M | $123M |
| Intangible assets | $20.4M | $22.0M | $24.0M | $25.7M | $27.9M | $29.0M | β | β | β | β |
| Total assets | $912M | $1.3B | $2.7B | $3.2B | $2.4B | $2.6B | $2.5B | $3.0B | $3.0B | $3.5B |
| Total liabilities | $813M | $957M | $1.5B | $1.5B | $1.6B | $1.8B | $2.0B | $2.6B | $2.4B | $3.0B |
| Shareholders' equity | $99.6M | $281M | $1.0B | $1.5B | $743M | $772M | $573M | $387M | $588M | $489M |
| Margins | ||||||||||
| Gross margin | 100.0% | 100.0% | 99.7% | 99.6% | 98.4% | 98.7% | 97.6% | 98.8% | 98.4% | 98.3% |
| Operating margin | β5.8% | 6.1% | β10.2% | 32.6% | β23.6% | β3.7% | β69.8% | β44.9% | β67.4% | β40.4% |
| EBITDA margin | β3.7% | 7.4% | β8.4% | 33.7% | β21.8% | β1.8% | β67.4% | β43.6% | β66.0% | β39.4% |
| Net margin | β17.4% | 0.1% | 45.6% | 24.8% | β60.9% | β3.5% | β45.9% | β46.5% | β64.4% | β40.4% |
| FCF margin | β34.4% | 27.5% | 98.3% | 28.0% | 0.1% | 2.3% | β49.4% | β42.1% | β77.5% | β33.9% |
| Returns | ||||||||||
| Return on capital employed | β2.6% | 2.9% | β2.6% | 12.4% | β9.6% | β1.3% | β18.5% | β13.9% | β17.6% | β13.9% |
| Return on equity | β60.7% | 0.2% | 41.2% | 22.1% | β40.1% | β3.8% | β40.1% | β76.3% | β93.1% | β70.8% |
| Return on assets | β6.6% | 0.0% | 13.7% | 9.4% | β15.8% | β1.1% | β10.5% | β13.3% | β15.1% | β11.7% |
| Return on tangible equity | β76.3% | 7.3% | 27.0% | 19.4% | β62.1% | β3.9% | β47.1% | β94.7% | β77.1% | β78.0% |
| Growth | ||||||||||
| Revenue growth | β | 46.5% | 18.1% | 87.2% | β35.0% | 11.1% | β27.5% | 34.1% | β10.5% | 33.8% |
| Net income growth | β | β | 79,015.9% | 1.6% | β259.7% | β | β | β | β | β |
| EPS growth | β | β | 1,280.0% | β8.2% | β267.4% | β | β | β | β | β |
| FCF growth | β | β | 322.8% | β46.6% | β99.8% | 2,340.9% | β1,639.4% | β | β | β |
| Share count change | β | 4.3% | 6.3% | 14.3% | β8.8% | 1.0% | 0.6% | 0.9% | 4.4% | 7.0% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β27.0x | β | β4.5x | β | β | β | β | β | β |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.5x | 1.1x | β | 2.1x | 3.4x | 2.1x | 3.7x |
| Interest coverage | β0.5x | 0.7x | β1.4x | 29.4x | β18.1x | β3.2x | β50.5x | β27.9x | β28.0x | β22.1x |
| Current ratio | 6.0x | 4.8x | 7.9x | 10.0x | 3.6x | 9.7x | 7.1x | 5.9x | 8.5x | 3.8x |
| Quick ratio | 6.0x | 4.8x | 7.8x | 9.9x | 3.5x | 9.6x | 7.0x | 5.9x | 8.4x | 3.8x |
| Capital allocation | ||||||||||
| Capex / revenue | 2.1% | 6.8% | 2.3% | 2.8% | 4.8% | 1.5% | 2.7% | 3.0% | 6.4% | 5.5% |
| Stock comp / revenue | 20.8% | 16.9% | 21.9% | 13.1% | 31.6% | 14.9% | 17.1% | 13.4% | 18.5% | 14.2% |
| Payouts / FCF | β | 0.0% | 0.0% | 10.9% | 11,729.0% | 0.0% | β | β | β | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 6.0 | 5.0 | 5.0 | 3.0 | 6.0 | 0.0 | 4.0 | 2.0 | 3.0 |
| Altman Z'' | 0.5 | 2.0 | 4.1 | 6.0 | 2.7 | 4.2 | 2.3 | 2.2 | 1.8 | 1.1 |
| Accruals ratio | 5.7% | β15.6% | β16.5% | β2.3% | β17.1% | β2.4% | 0.2% | β2.1% | 1.6% | β3.5% |
Source: SEC EDGAR XBRL filings (CIK 0000874015). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
